The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein

Area of Science:

• Molecular Biology
• Cell Signaling
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) is a known calmodulin-binding protein.
• Calmodulin (CaM) is a crucial calcium-binding protein involved in cellular signaling.
• ErbB2, a related receptor, is overexpressed in certain cancers, notably breast cancer.

Purpose of the Study:

• To determine if the ErbB2 receptor also binds to calmodulin.
• To investigate the role of CaM in regulating ErbB2 activity and its downstream signaling pathways.
• To explore the therapeutic potential of CaM modulation in ErbB2-driven cancers.

Main Methods:

• CaM-agarose pull-down assays and CaM-affinity chromatography to isolate ErbB2.
• Western blot analysis to detect ErbB2 and EGFR interactions.
• Overlay assays with biotinylated CaM to confirm direct binding to ErbB2.
• Cell-based assays using W7 (CaM antagonist) to assess effects on ErbB2 phosphorylation and downstream signaling pathways (ERK1/2, Akt/PKB, CREB, ATF1).

Main Results:

• ErbB2 was successfully pulled down by CaM in a calcium-dependent manner.
• Direct binding of CaM to ErbB2 was confirmed via overlay assays, dependent on calcium and specific to CaM.
• CaM antagonist W7 inhibited ErbB2 phosphorylation and downstream signaling kinases (ERK1/2, Akt/PKB).
• W7 treatment increased phosphorylation of CREB and ATF1, suggesting calcineurin pathway inhibition.

Conclusions:

• ErbB2 is a novel calmodulin-binding protein.
• Calmodulin plays a significant role in regulating ErbB2 activity and its downstream signaling in vivo.
• Targeting the CaM-ErbB2 interaction may offer a new therapeutic strategy for ErbB2-overexpressing cancers.